Learn more

REMD BIOTHERAPEUTICS INC

Overview
  • Total Patents
    57
  • GoodIP Patent Rank
    25,772
  • Filing trend
    ⇩ 64.0%
About

REMD BIOTHERAPEUTICS INC has a total of 57 patent applications. It decreased the IP activity by 64.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are SYLVAN PHARMACEUTICALS PTY LTD, KS BIOMEDIX LTD and MICROPHARM LTD.

Patent filings per year

Chart showing REMD BIOTHERAPEUTICS INCs patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Yan Hai 40
#2 Calzone Frank J 22
#3 Shi Jim 16
#4 Zhang John 14
#5 Oh Jeong 10
#6 Calzone Frank 6
#7 Fang Mei 4
#8 Jim Shi 2
#9 Hai Yan 2
#10 Frank J Calzone 1

Latest patents

Publication Filing date Title
EP3773717A1 Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
EP3755327A1 Calcitonin gene-related peptide (cgrp) antagonist antibodies
WO2019028182A2 Cancer treatment using antibodies that bind human cd134 (ox40) receptor
EP3585430A1 Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
CN110366564A Use the immunotherapy of the antibody combined with programmed death 1 (PD-1)
WO2018119475A1 Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)
CA3036273A1 Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
US2019002577A1 Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
WO2017062693A1 Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
US2017143673A1 Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
US2018256713A1 Methods for treating heart failure using glucagon receptor antagonistic antibodies
AU2016242935A1 Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
EP3151855A2 Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies